Dr. Jason Springer completed his general rheumatology fellowship followed by a vasculitis fellowship at Cleveland Clinic. He completed a Master of Science in Clinical and Translational Research at Kansas University and went on to serve as the Director of the Vasculitis Center at the University of Kansas Medical Center (KUMC) from 2013 to 2020. He also served as co-director of the Clinical Trials Unit for the Division of Allergy, Clinical Immunology, and Rheumatology for KUMC. He serves on the board of directors and chairs the research committee for the Vasculitis Foundation. He has served as an organizer, moderator, and speaker for the Vasculitis Foundation Regional Kansas City Patient Vasculitis Symposium in 2014, 2016, and 2018. He serves on the literature review committee for the development of the 2020 American College of Rheumatology Vasculitis Guidelines.
Dr. Springer’s research interests have been focused on translational and clinical studies in forms of primary systemic vasculitis. He has multiple abstracts and publications on the role of mast cells in vascular inflammation and Kawasaki’s disease. He is the principal investigator for a clinical trial evaluating the development of immunogenicity in patients with ANCA-associated vasculitis receiving rituximab for maintenance therapy. He has served as a collaborator on many multi-center trials with the Vasculitis Clinical Research Consortium (VCRC). He also serves a role in the development of the Vasculitis-Patient Powered Research Network (V-PPRN), which is a prospective, internet-based, patient-reported registry with over 2,000 participants internationally. He has served as co-principal investigator of several studies utilizing the V-PPRN.